Flight Centre Travel Group Ltd. (AU000000FLT9)
XSTU 
Summary
AU000000FLT9 Chart
Volatus Aerospace Inc. Secures $3 Million in Financing from Existing Major Institutional Investor and Provides Corporate Update
/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”), a leader in global aerial solutions, is pleased to announce the successful closing of a $3 million private placement (the “Financing”) from Investissement Québec. Pursuant to the Financing, the Company entered into an amended and restated secured convertible debenture (the “Debenture”) increasing the principal amount of Investissement Québec's original investment of $7.5 million, as announced in the Company's news release dated October 21, 2024, to an aggregate of $10.5 million.
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib
Flight Centre Travel Group Ltd. Dividends
Flight Centre Travel Group Ltd. Earnings
| 5 Feb 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 1 May 2024 Date | | 4.1 Cons. EPS | - EPS |
| 7 Feb 2024 Date | | 4.48 Cons. EPS | 4.44 EPS |
| 5 Feb 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 1 May 2024 Date | | 4.1 Cons. EPS | - EPS |
| 7 Feb 2024 Date | | 4.48 Cons. EPS | 4.44 EPS |
Flight Centre Travel Group Ltd. (AU000000FLT9) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Flight Centre Travel Group Ltd. ever had a stock split?
Flight Centre Travel Group Ltd. Profile
| Software - Infrastructure Industry | Technology Sector | Mr. Ronald F. Clarke CEO | XSTU Exchange | US3390411052 ISIN |
| US Country | 10,500 Employees | - Last Dividend | - Last Split | 15 Dec 2010 IPO Date |
Overview
FLEETCOR Technologies, Inc. is a prominent payments company that facilitates a wide range of expense management solutions for businesses and consumers, particularly those related to vehicle, lodging, and corporate payments. Having a global footprint, the company operates not only in the United States but also has a significant presence in Brazil, the United Kingdom, and other international markets. The company's operations are segmented into Vehicle Payments, Corporate Payments, Lodging Payments, and Others, demonstrating a diversified portfolio of payment solutions. Founded in 1986 and headquartered in Atlanta, Georgia, FLEETCOR has grown to become a key player in the payment solutions sector, serving a wide array of customers including businesses, merchants, consumers, and payment networks.
Products and Services
FLEETCOR Technologies, Inc. offers a comprehensive array of products and services tailored to meet the specific needs of their clients, ranging from vehicle payment solutions to corporate payment systems and beyond:
- Vehicle Payment Solutions: These include a variety of services to manage expenses related to fuel, tolls, parking, fleet maintenance, and long-haul transportation. These solutions are designed to streamline the management of vehicle-related expenses for businesses.
- Prepaid Food and Transportation Vouchers and Cards: FLEETCOR offers prepaid solutions to cover food and transportation expenses, providing an efficient way for businesses to manage these costs for their employees or customers.
- Corporate Payment Solutions: This range includes a suite of products aimed at simplifying the corporate payments process, such as accounts payable automation, virtual cards, cross-border payments solutions, and purchasing as well as travel and entertainment card products. These solutions are crafted to enhance operational efficiencies in corporate financial transactions.
- Lodging Payments Solutions: Tailored for employees traveling overnight for work, traveling crews, and stranded passengers from airlines and cruise lines, as well as insurance policyholders displaced from their homes due to damage or catastrophe, these solutions facilitate the simplification of managing lodging expenses under various circumstances.
- Gifts and Payroll Cards: FLEETCOR also provides gift and payroll card products, offering an alternative and possibly more convenient method for businesses to distribute rewards or payroll to their employees.
Contact Information
